


antitumor efficacy against L-1210 was expressed as a percentage of the mean survival time (MST) of the control group after measuring MST:

$$T/C = \frac{\text{MST of the test group}}{\text{MST of the control group}} \times 100 (\%)$$

The T/C value of the compound in Example 3 at a dose of 25 mg/kg was 243% whereas the T/C value of 2'-deoxy-2'-methylidenecytidine at the same dose was 152%.

We claim:

1. A pyrimidine 2'-deoxy-2'-methylidene nucleoside compound of the formula:



wherein R<sup>1</sup> represents amino [or], hydroxy or acylamino having 2 to 30 carbon atoms; R<sup>2</sup> represents hydrogen, halogen, a lower alkyl, a lower alkenyl, a lower alkynyl or a haloalkyl; R<sup>3</sup> and R<sup>4</sup> may be the same or different and represent hydrogen, [stearoyl] acyl having 2 to 30 carbon atoms or aminoacyl, or a pharmaceutically acceptable salt or hydrate thereof, [except] excluding the case [that] where R<sup>1</sup> is amino or hydroxy, and both of R<sup>3</sup> and R<sup>4</sup> [may be] are hydrogen.]

2. A compound or a pharmaceutically acceptable salt or hydrate thereof as claimed in claim 1 which is selected from the group consisting of 2'-deoxy-2'-methylidene-5'-O-stearoylcytidine and 5'-O-(2-amino-3-methylvaleryl)-2'-deoxy-2'-methylidenecytidine.

3. A pyrimidine 2'-deoxy-2'-methylidene nucleoside compound or a pharmaceutically acceptable salt or hydrate thereof as claimed in Claim 1, which is 2'-deoxy-2'-methylidene-N<sup>4</sup>-decanoylcytidine.

4. A pyrimidine 2'-deoxy-2'-methylidene nucleoside compound or a pharmaceutically acceptable salt or hydrate thereof as claimed in Claim 1, which is 2'-deoxy-2'-methylidene-N<sup>4</sup>-stearoylcytidine.

5. A pyrimidine 2'-deoxy-2'-methylidene nucleoside compound or a pharmaceutically acceptable salt or hydrate thereof as claimed in Claim 1, which is 5'-O-decanoyl-2'-deoxy-2'-methylidenecytidine.

6. A pyrimidine 2'-deoxy-2'-methylidene nucleoside compound or a pharmaceutically acceptable salt or hydrate thereof as claimed in Claim 1, which is 5'-O-myristoyl-2'-deoxy-2'-methylidenecytidine.

7. A pyrimidine 2'-deoxy-2'-methylidene nucleoside compound or a pharmaceutically acceptable salt or hydrate thereof as claimed in claim 1, which is 5'-O-palmitoyl-2'-deoxy-2'-methylidenecytidine.

8. A pyrimidine 2'-deoxy-2'-methylidene nucleoside compound or a pharmaceutically acceptable salt or hydrate thereof as claimed in Claim 1, which is 2'-deoxy-2'-methylidene-5'-O-stearoylcytidine.]

9. A composition comprising a compound or a pharmaceutically acceptable salt or hydrate thereof as claimed in Claim 1.

10. A composition for oral administration comprising a compound or a pharmaceutically acceptable salt or hydrate thereof as claimed in Claim 1.

add 8  
add 21